Graphical Abstract
Advancing the research on management of global airway disease: insights from a post hoc analysis
Volume: 63 - Issue: 1
First page: 1 - Last page: 1
S. Toppila-Salmi
DOI: 10.4193/Rhin25.901
Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) frequently coexist, forming a complex multimorbid condition often referred to as “global airway disease.” This concept reflects shared pathophysiological mechanisms of eosinophilic inflammation and underscores the need for integrated treatment strategies targeting both upper and lower airway manifestations (1). The burden of severe CRSwNP, asthma, and N-ERD is substantial, particularly in terms of reduced quality of life, recurrent exacerbations, revision endoscopic sinus surgeries (ESS), and healthcare utilization (2). Biologics represent a significant advancement in the treatment of global airway diseases.
Rhinology 63-1: 1-1, 2025
